Table 2.
Group I (n = 60) | Group II (n = 60) | Group III (n = 60) | Test of Significance | p | |
---|---|---|---|---|---|
A2M-AS1 | |||||
Median (Min–Max) | 1.75 (0.58–2.80) | 1.65 (0.20–4.78) | 0.44 (0.02–1.0) | H = 100.629 * | <0.001 * |
Significance between Groups | p1 = 0.368, p2 < 0.001 *, p3 < 0.001 * | ||||
FLVCR1 | |||||
Median (Min–Max) | 1.38 (0.08–3.83) | 0.94 (0.12–4.56) | 0.48 (0.01–11.25) | H = 24.269 * | <0.001 * |
Significance between Groups | p1 = 0.092, p2 < 0.001 *, p3 = 0.002 * | ||||
DBH-AS1 | |||||
Median (Min–Max) | 2.45 (0.01–7.62) | 5.85 (0.19–11.0) | 14.58 (0.25–51.0) | H = 68.041 * | <0.001 * |
Significance between Groups | p1 < 0.001 *, p2 < 0.001 *, p3 < 0.001 * | ||||
FLVCR1-DT | |||||
Median (Min–Max) | 0.70 (0.30–1.0) | 7.45 (2.40–11.0) | 12.70 (2.0–77.0) | H = 131.159 * | <0.001 * |
Significance between Groups | p1 < 0.001 *, p2 < 0.001 *, p3 = 0.001 * | ||||
NCBP2AS2-1 | |||||
Median (Min–Max) | 0.45 (0.13–1.10) | 2.81 (1.51–3.81) | 8.98 (2.13–45.77) | H = 151.736 * | <0.001 * |
Significance between Groups | p1 < 0.001 *, p2 < 0.001 *, p3 < 0.001 * | ||||
CO-RADS | |||||
Median (Min–Max) | – | 2.0 (1.0–2.0) | 3.0 (3.0–5.0) | U = 0.0 * | <0.001 * |
SD: Standard deviation; F: F for ANOVA test, pairwise comparison between two groups were performed using the post hoc test (Tukey); H: H for the Kruskal–Wallis test, pairwise comparison between two groups were performed using the post hoc test (Dunn’s for multiple comparisons test); p: p-value for comparing the studied groups; p1: p-value for the comparison of Group I and Group II; p2: p-value for the comparison of Group I and Group III; p3: p-value for the comparison of Group II and Group III. *: Statistically significant at p ≤ 0.05. Group I: Control group; Group II: Moderate COVID-19 infection; Group III: Severe COVID-19 infection.